Hi HardmanoMYX certainly has a great looking chart and volume...

Hi Hardmano

MYX certainly has a great looking chart and volume has been steadily increasing as more interest seems to be coming into the stock.


Will be looking for an update on the partnership with HPPI on the progress of SUBA Itraconazole and the potential treatment for certain types of cancers. Itraconazole originally was used to treat fungal infections and already is an FDA approved product which bodes well for further testing a less red tape.

Mayne Pharma’s Doxycycline Hyclate Delayed-Release Tablet are authorized generic versions of the Doryx products in 75mg and 100mg which will be the first revenue from the Metrics acquisition and will be IMO a huge addition to the portfolio of MYX.

The acquisition of Libertas which has 6 marketed ANDA products and 2 pipeline ANDA and the founder Chris Schneider, has joined MYX US team.


20 generic products under development


7 Generic products filed with the FDA Targeting US


12 injectable products filed with the TGA


Also not to forget additional products such as SUBACAP to be released in 2014 to the UK & Spain and Italy and Portugal in 2015.


So there is plenty to keep management busy over the next couple of years and plenty of options to create wealth for its shareholders.

Cheers Matsim